Lymphocytes regulate expression of the SARS-CoV-2 cell entry factor ACE2 in the pancreas of T2DM patients.
Diabet Med
; : e15106, 2023 Apr 04.
Article
Dans Anglais
| MEDLINE | ID: covidwho-2288602
ABSTRACT
AIMS:
COVID-19 patients with type 2 diabetes mellitus (T2DM) show both poorer clinical outcomes and have an increased risk of death. SARS-CoV-2 virus infection requires simultaneous expression of the SARS-CoV-2 cell entry factors angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine type 2 (TMPRSS2) in the same cell. The aim of the study was to explore the underlying mechanisms of a COVID-19 infection in patients with T2DM.METHODS:
The distribution and expression of AEC2 and TMPRSS2 in different pancreatic cell types in clinical samples of T2DM patients and diabetic mouse models were analysed by single-cell sequencing, bioinformatics analysis and basic experiments.RESULTS:
The results showed that ACE2 and TMPRSS2 are expressed in the ducts of the human pancreas. These findings suggest that SARS-CoV-2 can infect ductal cells in vivo through ACE2 and TMPRSS2. T2DM can promote the co-expression of ACE2 and TMPRSS2 in exocrine ducts, including in the human pancreas. We hypothesize that ACE2 expression levels are associated with increased numbers of lymphocytes in vivo.CONCLUSIONS:
Increased blood glucose levels are associated with increased ACE2 expression and an increased number of lymphocytes. At the same time, lymphocytes can promote ACE2 expression.
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Type d'étude:
Étude pronostique
langue:
Anglais
Revue:
Diabet Med
Thème du journal:
Endocrinologie
Année:
2023
Type de document:
Article
Pays d'affiliation:
Dme.15106
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS